Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction
Bradykinin is a potent vasoactive peptide that is known to elicit a number of biological responses. A number of peptidases have been identified to possess kininase activity, the inhibition of which increases the availability and effectiveness of kinins. We wished to determine the cardioprotective ac...
Gespeichert in:
| Veröffentlicht in: | Pharmacological research 2003-12, Vol.48 (6), p.557-563 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 563 |
|---|---|
| container_issue | 6 |
| container_start_page | 557 |
| container_title | Pharmacological research |
| container_volume | 48 |
| creator | Veeravalli, K.K. Akula, A. Routhu, K.V. Kota, M.K. |
| description | Bradykinin is a potent vasoactive peptide that is known to elicit a number of biological responses. A number of peptidases have been identified to possess kininase activity, the inhibition of which increases the availability and effectiveness of kinins. We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30
min) and reperfusion (4
h). Myocardial infarction was produced by occlusion of the left anterior descending coronary artery for 30
min followed by 4
h of reperfusion. Infarct size was measured by using the staining agent 2,3,5-triphenyl tetrazolium chloride (TTC). Lipid peroxide levels in serum and in heart tissue were estimated spectrophotometrically. A lead II electrocardiogram was monitored at various intervals throughout the experiment. Infarct size was reduced to a greater extent with apstatin and with combined inhibition it was further reduced. Infarct size reduction obtained with the combined inhibition came to normal with the prior administration of B
2 bradykinin antagonist HOE140 suggests the involvement of bradykinin in the cardioprotective actions of apstatin. |
| doi_str_mv | 10.1016/S1043-6618(03)00222-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75766612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043661803002226</els_id><sourcerecordid>75766612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-25c78cf4641597ebe9efdc9fdaed676ca6d7302ce8631ff05edee4c9923fcae23</originalsourceid><addsrcrecordid>eNqFkctO5TAMhiMEAgZ4BEZZIUaaQtJL2q4QQtwkJBbAOvJJHCajNjmT9AyXN-FtSXsqsWQV-9dnO_ZPyCFnJ5xxcfrAWVlkQvDmmBW_GMvzPBMbZJezVmScN2JzjGdkh_yI8S9jrC052yY7vKzyuuHtLvm4dQaCGmi070g729vBumeKxmASvaGwjAMkjULnHVJwmqZE-X5hXdK9oy92-EPRQQfLYLvfqUm0zo_xRAfo7ZSksgBDnPnXJQbboxugo_2bVxC0hRGavpP67pMtA13Eg_ndI09Xl48XN9nd_fXtxfldpgrBhyyvVN0oU4qSV22NC2zRaNUaDahFLRQIXRcsV9iIghvDKtSIpWrbvDAKMC_2yNG67zL4fyuMg-xtVNh14NCvoqyrWqQbjmC1BlXwMQY0Mq3VQ3iTnMnREzl5IseDS1bIyRMpUt3PecBq0aP-qppNSMDZGsC05n-LQUZl0SnUNiQXpPb2mxGfZtSgzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75766612</pqid></control><display><type>article</type><title>Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Veeravalli, K.K. ; Akula, A. ; Routhu, K.V. ; Kota, M.K.</creator><creatorcontrib>Veeravalli, K.K. ; Akula, A. ; Routhu, K.V. ; Kota, M.K.</creatorcontrib><description>Bradykinin is a potent vasoactive peptide that is known to elicit a number of biological responses. A number of peptidases have been identified to possess kininase activity, the inhibition of which increases the availability and effectiveness of kinins. We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30
min) and reperfusion (4
h). Myocardial infarction was produced by occlusion of the left anterior descending coronary artery for 30
min followed by 4
h of reperfusion. Infarct size was measured by using the staining agent 2,3,5-triphenyl tetrazolium chloride (TTC). Lipid peroxide levels in serum and in heart tissue were estimated spectrophotometrically. A lead II electrocardiogram was monitored at various intervals throughout the experiment. Infarct size was reduced to a greater extent with apstatin and with combined inhibition it was further reduced. Infarct size reduction obtained with the combined inhibition came to normal with the prior administration of B
2 bradykinin antagonist HOE140 suggests the involvement of bradykinin in the cardioprotective actions of apstatin.</description><identifier>ISSN: 1043-6618</identifier><identifier>EISSN: 1096-1186</identifier><identifier>DOI: 10.1016/S1043-6618(03)00222-6</identifier><identifier>PMID: 14527819</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject><![CDATA[Angiotensin-Converting Enzyme Inhibitors - administration & dosage ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Animals ; Bradykinin ; Bradykinin - administration & dosage ; Bradykinin - analogs & derivatives ; Bradykinin Receptor Antagonists ; Cardioprotection ; Drug Therapy, Combination ; Enalapril - administration & dosage ; Enalapril - therapeutic use ; Female ; Heart Rate - drug effects ; Infarction ; Ischemia ; Lipid Peroxides - analysis ; Lipid Peroxides - blood ; Lisinopril - administration & dosage ; Lisinopril - therapeutic use ; Male ; Malondialdehyde - analysis ; Malondialdehyde - blood ; Myocardial Infarction - etiology ; Myocardial Infarction - pathology ; Myocardial Infarction - prevention & control ; Myocardial Reperfusion Injury - complications ; Myocardial Reperfusion Injury - physiopathology ; Myocardium - chemistry ; Myocardium - pathology ; Peptides - administration & dosage ; Peptides - therapeutic use ; Ramipril - administration & dosage ; Ramipril - therapeutic use ; Rats ; Rats, Sprague-Dawley ; Reperfusion ; Time Factors]]></subject><ispartof>Pharmacological research, 2003-12, Vol.48 (6), p.557-563</ispartof><rights>2003 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-25c78cf4641597ebe9efdc9fdaed676ca6d7302ce8631ff05edee4c9923fcae23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S1043-6618(03)00222-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14527819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Veeravalli, K.K.</creatorcontrib><creatorcontrib>Akula, A.</creatorcontrib><creatorcontrib>Routhu, K.V.</creatorcontrib><creatorcontrib>Kota, M.K.</creatorcontrib><title>Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction</title><title>Pharmacological research</title><addtitle>Pharmacol Res</addtitle><description>Bradykinin is a potent vasoactive peptide that is known to elicit a number of biological responses. A number of peptidases have been identified to possess kininase activity, the inhibition of which increases the availability and effectiveness of kinins. We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30
min) and reperfusion (4
h). Myocardial infarction was produced by occlusion of the left anterior descending coronary artery for 30
min followed by 4
h of reperfusion. Infarct size was measured by using the staining agent 2,3,5-triphenyl tetrazolium chloride (TTC). Lipid peroxide levels in serum and in heart tissue were estimated spectrophotometrically. A lead II electrocardiogram was monitored at various intervals throughout the experiment. Infarct size was reduced to a greater extent with apstatin and with combined inhibition it was further reduced. Infarct size reduction obtained with the combined inhibition came to normal with the prior administration of B
2 bradykinin antagonist HOE140 suggests the involvement of bradykinin in the cardioprotective actions of apstatin.</description><subject>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Animals</subject><subject>Bradykinin</subject><subject>Bradykinin - administration & dosage</subject><subject>Bradykinin - analogs & derivatives</subject><subject>Bradykinin Receptor Antagonists</subject><subject>Cardioprotection</subject><subject>Drug Therapy, Combination</subject><subject>Enalapril - administration & dosage</subject><subject>Enalapril - therapeutic use</subject><subject>Female</subject><subject>Heart Rate - drug effects</subject><subject>Infarction</subject><subject>Ischemia</subject><subject>Lipid Peroxides - analysis</subject><subject>Lipid Peroxides - blood</subject><subject>Lisinopril - administration & dosage</subject><subject>Lisinopril - therapeutic use</subject><subject>Male</subject><subject>Malondialdehyde - analysis</subject><subject>Malondialdehyde - blood</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - pathology</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Myocardial Reperfusion Injury - complications</subject><subject>Myocardial Reperfusion Injury - physiopathology</subject><subject>Myocardium - chemistry</subject><subject>Myocardium - pathology</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - therapeutic use</subject><subject>Ramipril - administration & dosage</subject><subject>Ramipril - therapeutic use</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Reperfusion</subject><subject>Time Factors</subject><issn>1043-6618</issn><issn>1096-1186</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctO5TAMhiMEAgZ4BEZZIUaaQtJL2q4QQtwkJBbAOvJJHCajNjmT9AyXN-FtSXsqsWQV-9dnO_ZPyCFnJ5xxcfrAWVlkQvDmmBW_GMvzPBMbZJezVmScN2JzjGdkh_yI8S9jrC052yY7vKzyuuHtLvm4dQaCGmi070g729vBumeKxmASvaGwjAMkjULnHVJwmqZE-X5hXdK9oy92-EPRQQfLYLvfqUm0zo_xRAfo7ZSksgBDnPnXJQbboxugo_2bVxC0hRGavpP67pMtA13Eg_ndI09Xl48XN9nd_fXtxfldpgrBhyyvVN0oU4qSV22NC2zRaNUaDahFLRQIXRcsV9iIghvDKtSIpWrbvDAKMC_2yNG67zL4fyuMg-xtVNh14NCvoqyrWqQbjmC1BlXwMQY0Mq3VQ3iTnMnREzl5IseDS1bIyRMpUt3PecBq0aP-qppNSMDZGsC05n-LQUZl0SnUNiQXpPb2mxGfZtSgzQ</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>Veeravalli, K.K.</creator><creator>Akula, A.</creator><creator>Routhu, K.V.</creator><creator>Kota, M.K.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031201</creationdate><title>Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction</title><author>Veeravalli, K.K. ; Akula, A. ; Routhu, K.V. ; Kota, M.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-25c78cf4641597ebe9efdc9fdaed676ca6d7302ce8631ff05edee4c9923fcae23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - administration & dosage</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Animals</topic><topic>Bradykinin</topic><topic>Bradykinin - administration & dosage</topic><topic>Bradykinin - analogs & derivatives</topic><topic>Bradykinin Receptor Antagonists</topic><topic>Cardioprotection</topic><topic>Drug Therapy, Combination</topic><topic>Enalapril - administration & dosage</topic><topic>Enalapril - therapeutic use</topic><topic>Female</topic><topic>Heart Rate - drug effects</topic><topic>Infarction</topic><topic>Ischemia</topic><topic>Lipid Peroxides - analysis</topic><topic>Lipid Peroxides - blood</topic><topic>Lisinopril - administration & dosage</topic><topic>Lisinopril - therapeutic use</topic><topic>Male</topic><topic>Malondialdehyde - analysis</topic><topic>Malondialdehyde - blood</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - pathology</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Myocardial Reperfusion Injury - complications</topic><topic>Myocardial Reperfusion Injury - physiopathology</topic><topic>Myocardium - chemistry</topic><topic>Myocardium - pathology</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - therapeutic use</topic><topic>Ramipril - administration & dosage</topic><topic>Ramipril - therapeutic use</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Reperfusion</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Veeravalli, K.K.</creatorcontrib><creatorcontrib>Akula, A.</creatorcontrib><creatorcontrib>Routhu, K.V.</creatorcontrib><creatorcontrib>Kota, M.K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Veeravalli, K.K.</au><au>Akula, A.</au><au>Routhu, K.V.</au><au>Kota, M.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction</atitle><jtitle>Pharmacological research</jtitle><addtitle>Pharmacol Res</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>48</volume><issue>6</issue><spage>557</spage><epage>563</epage><pages>557-563</pages><issn>1043-6618</issn><eissn>1096-1186</eissn><abstract>Bradykinin is a potent vasoactive peptide that is known to elicit a number of biological responses. A number of peptidases have been identified to possess kininase activity, the inhibition of which increases the availability and effectiveness of kinins. We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30
min) and reperfusion (4
h). Myocardial infarction was produced by occlusion of the left anterior descending coronary artery for 30
min followed by 4
h of reperfusion. Infarct size was measured by using the staining agent 2,3,5-triphenyl tetrazolium chloride (TTC). Lipid peroxide levels in serum and in heart tissue were estimated spectrophotometrically. A lead II electrocardiogram was monitored at various intervals throughout the experiment. Infarct size was reduced to a greater extent with apstatin and with combined inhibition it was further reduced. Infarct size reduction obtained with the combined inhibition came to normal with the prior administration of B
2 bradykinin antagonist HOE140 suggests the involvement of bradykinin in the cardioprotective actions of apstatin.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>14527819</pmid><doi>10.1016/S1043-6618(03)00222-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-6618 |
| ispartof | Pharmacological research, 2003-12, Vol.48 (6), p.557-563 |
| issn | 1043-6618 1096-1186 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75766612 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage Angiotensin-Converting Enzyme Inhibitors - therapeutic use Animals Bradykinin Bradykinin - administration & dosage Bradykinin - analogs & derivatives Bradykinin Receptor Antagonists Cardioprotection Drug Therapy, Combination Enalapril - administration & dosage Enalapril - therapeutic use Female Heart Rate - drug effects Infarction Ischemia Lipid Peroxides - analysis Lipid Peroxides - blood Lisinopril - administration & dosage Lisinopril - therapeutic use Male Malondialdehyde - analysis Malondialdehyde - blood Myocardial Infarction - etiology Myocardial Infarction - pathology Myocardial Infarction - prevention & control Myocardial Reperfusion Injury - complications Myocardial Reperfusion Injury - physiopathology Myocardium - chemistry Myocardium - pathology Peptides - administration & dosage Peptides - therapeutic use Ramipril - administration & dosage Ramipril - therapeutic use Rats Rats, Sprague-Dawley Reperfusion Time Factors |
| title | Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T08%3A40%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infarct%20size%20limiting%20effect%20of%20apstatin%20alone%20and%20in%20combination%20with%20enalapril,%20lisinopril%20and%20ramipril%20in%20rats%20with%20experimental%20myocardial%20infarction&rft.jtitle=Pharmacological%20research&rft.au=Veeravalli,%20K.K.&rft.date=2003-12-01&rft.volume=48&rft.issue=6&rft.spage=557&rft.epage=563&rft.pages=557-563&rft.issn=1043-6618&rft.eissn=1096-1186&rft_id=info:doi/10.1016/S1043-6618(03)00222-6&rft_dat=%3Cproquest_cross%3E75766612%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75766612&rft_id=info:pmid/14527819&rft_els_id=S1043661803002226&rfr_iscdi=true |